Oct 31 2009
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
“We are excited to be the first laboratory to offer GastroFISH for the colon. Using current histological techniques, identifying adenomas with a high risk for progression to cancer is not possible. Multi-target FISH will be helpful in the identification of these adenomas in conjunction with histology,” said Junqi Qian, M.D., Director of Molecular Diagnostics at Bostwick Laboratories®.
GastroFISH™ is a diagnostic test with a high sensitivity and specificity that will aid in the differential diagnosis of adenoma from adenocarcinoma. The results from GastroFISH™ together with a pathology diagnosis will assist the physician in guiding a more effective treatment plan for his/her patient.
NYU Langone strengthens world-leading GI cancer program with renowned leaders